Literature DB >> 10843197

Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure.

J S Powell1, S L Wardlaw, K D Post, P U Freda.   

Abstract

Radiation therapy (RT) has traditionally been considered a useful additional therapy for patients with acromegaly not achieving biochemical remission after surgery. However, recent evidence has suggested that RT is not curative in most patients with acromegaly when normalization of the serum insulin-like growth factor I (IGF-I) level is used to define remission. Therefore, we evaluated the success of RT based on IGF-I level in the 47 patients who received RT as part of their treatment from the cohort of 161 patients with acromegaly seen by us between 1981 and 1999. Four patients in whom no post-RT IGF-I level was available were excluded from the analysis. Of the remaining 43 patients, 32 patients received external beam RT, 6 received fractionated stereotactic radiosurgery, 4 received gamma-knife RT, and 1 received proton beam RT. The most recent IGF-I levels in these 43 patients, obtained a mean of 5.2 yr post-RT (range, 0.8-13.2 yr), were compared to age-adjusted normal ranges. IGF-I levels were normal in 17 patients (39.5%) without the addition of medical therapy. The percentage of patients with a normal IGF-I level generally increased with time post-RT; 27% of patients less than 6 yr post-RT, but 69.2% of patients 6 yr or more post-RT had normal IGF-I levels. Using the more traditional criterion for cure, a random GH measurement, 74% of patients had a GH level below 5 ng/mL, and 44% had a GH level below 2.5 ng/mL and would have been considered in remission based on these criteria. We conclude that with time RT remains a useful adjunctive treatment for many patients with acromegaly. RT should be considered along with appropriate medical therapy in selected patients who do not achieve normalization of IGF-I level after surgery or for those resistant to medical therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843197     DOI: 10.1210/jcem.85.5.6586

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  Radiotherapy and radiosurgery in acromegaly.

Authors:  Frédéric Castinetti; Isabelle Morange; Henry Dufour; Jean Regis; Thierry Brue
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

2.  Efficacy and safety of CyberKnife radiosurgery for acromegaly.

Authors:  Brian K Roberts; Daniel L Ouyang; Shivanand P Lad; Steven D Chang; Griffith R Harsh; John R Adler; Scott G Soltys; Iris C Gibbs; Lynn Remedios; Laurence Katznelson
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 3.  Updates in outcomes of stereotactic radiation therapy in acromegaly.

Authors:  Monica Livia Gheorghiu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications.

Authors:  Thomas J Wilson; Erin L McKean; Ariel L Barkan; William F Chandler; Stephen E Sullivan
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

Review 5.  Medical management of growth hormone-secreting pituitary adenomas.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 6.  Management of acromegaly: is there a role for primary medical therapy?

Authors:  Zachary M Bush; Mary Lee Vance
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 7.  Current status and future opportunities for controlling acromegaly.

Authors:  Shlomo Melmed; Mary Lee Vance; Ariel L Barkan; Bengt-Ake Bengtsson; David Kleinberg; Anne Klibanski; Peter J Trainer
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 8.  Pharmacological therapy for acromegaly: a critical review.

Authors:  Alex F Muller; Aart Jan Van Der Lely
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Lanreotide Autogel: a review of its use in the management of acromegaly.

Authors:  Jamie D Croxtall; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.